Pulse Biosciences (PLSE) announced the enrollment of the first patient in its NANOCLAMP AF study for the treatment of atrial fibrillation. The successful first procedure was completed at St. Helena Hospital in St. Helena, California, with the nPulse Cardiac Surgical System following its recent FDA IDE approval.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE: